Form 4 for EDIT Editas Medicine, Inc.
Accepted 2026-06-05 16:33:02 ET · period of report 2026-06-03 · accession 0001650664-26-000056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-05 16:33 | 2026-06-03 | EDIT | O'Neill Gilmore Neil | CEO, Dir | S - Sale | $2.70 | -15.4K | 248.3K | -6% | -$41.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-03 | S | D | 15,380 | $2.70 | 248,313 | D | — | — | (F1) Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. (F2) This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |